Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Nxera Pharma announced that it has achieved a second development milestone under its 2022 multi‑target collaboration and license agreement with Eli Lilly focused on diabetes and metabolic diseases. The milestone validates the NxWave™ GPCR structure‑based drug design platform, confirming its ability to (1) identify small‑molecule binders to GPCR targets and (2) solve receptor structures with bound ligands. A payment from Lilly was received, but the amount is undisclosed. Under the agreement Nxera remains eligible for up to US$694 million in additional development and commercial milestones plus tiered royalties on worldwide sales of any resulting products.

• New cash flow: The undisclosed payment provides immediate liquidity; however, the size is unknown, limiting quantitative assessment.
• Future upside: The $694 M ceiling represents a material long‑term revenue stream if candidates progress to later stages and achieve commercial success.
• Platform validation: Demonstrating both binder discovery and structural resolution strengthens confidence in NxWave™ and may improve partner perception, potentially facilitating future collaborations or out‑licensing deals (e.g., the GPR52 program re‑licensing effort).
• Comparison with prior news: Earlier updates (Feb 2026 milestone from Centessa, Jan 2026 licensing of vamorolone, Dec 2025 regain of GPR52 rights) were routine or incremental. The Lilly milestone is the first development trigger from a major Big‑Pharma partner on the metabolic disease front, moving beyond earlier financing and licensing activities.
• Market expectations: Analysts likely priced in the possibility of future Lilly milestones but not the timing or certainty of a second development trigger; therefore the news is unexpectedly positive and material.

Nxera Pharma is a Japanese‑based biopharma focused on GPCR‑targeted drug discovery using its proprietary NxWave™ platform (structure‑based design + AI). Flagship projects include:
- Metabolic disease pipeline (partnered with Eli Lilly) – leveraging GPCR targets for diabetes/obesity.
- Daridorexant (QUVIVIQ®) – dual orexin receptor antagonist already marketed in Japan, now seeking approval in South Korea.
- Vamorolone (AGAMREE®) – licensed from Santhera for Duchenne Muscular Dystrophy in APAC.
- GPR52 agonist program (NXE‑149) – schizophrenia candidate being re‑licensed after Boehringer Ingelheim declined its option.
- Obesity pipeline – oral GLP‑1 agonist + six GPCR programs launched Q3 2025.